

Supplementary Information

for

Phosphorus Oxychloride as an Efficient Coupling Reagent for the Synthesis of Ester, Amide and Peptide under Mild Conditions

Hu Chen,^{*a,b} Xunfu Xu,^a Liu Leo Liu,^a Guo Tang,^{*a} Yufen Zhao^a

^a Department of Chemistry, College of Chemistry and Chemical Engineering, and the Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, Fujian 361005, China

^b Department of Chemistry and Chemical Engineering, Hefei Normal University, Hefei 230601, China

hchen808@yahoo.cn; t12g21@xmu.edu.cn

Table of Contents

Genera	2
Spectral Data	3-10
Copies of ¹ H, ¹³ C, and HPLC spectra	11-45


General:

All reactions were carried out under N₂ atmosphere. All reagents were purchased and used without further purification. The solvent was freshly distilled. All new compounds were further characterized by HRMS(ESI).

Typical Procedure for Ester/Amide Synthesis. A solution of acid (0.5 mmol), alcohol or amine (0.6 mmol) and triethylamine (1.2 mmol) in anhydrous CH₂Cl₂ (1.5 mL) under N₂ atmosphere was added a solution of DMAP (0.15 mmol) in anhydrous CH₂Cl₂ (0.5 mL). After stirring for 5 min, POCl₃ (0.5 mmol) in anhydrous CH₂Cl₂ (1 mL) was added into the above reaction. After completion of reaction at room temperature (ca. 2 h, monitored through TLC), the reaction mixture was diluted with CH₂Cl₂(30 mL). The organic phase was washed sequentially with ice-cooled water(10 mL), 10% aqueous HCl (10 mL), saturated aqueous NaHCO₃ solution (10 mL), and brine. Drying over anhydrous Na₂SO₄, removal of solvent under vacuum, and purification of the residue by silica gel column chromatography (petroleum ether/ethyl acetate 9/1~5/1) afforded the pure product.


Synthesis of Dipeptide: A solution of the *N*-protected amino acid (0.5 mmol), methyl ester of amino acid hydrochloride (0.6 mmol) and triethylamine (1.8 mmol) in anhydrous CH₂Cl₂ (1.5 mL) under N₂ atmosphere was added a solution of 4-(dimethylamino) pyridine (0.15 mmol) in anhydrous CH₂Cl₂ (0.5 mL). After stirring for 5 min, the reaction mixture was added a solution of the POCl₃ (0.5 mmol) in anhydrous CH₂Cl₂ (1 mL), and stirring was continued at room temperature. After completion of reaction (ca. 2 h, TLC monitoring), the reaction mixture was diluted with CH₂Cl₂(30 mL). The organic phase was washed sequentially with ice-cooled water(10 mL), 10% aqueous HCl (10 mL), saturated aqueous NaHCO₃ solution (10 mL), and brine. Drying over anhydrous Na₂SO₄, removal of solvent under vacuum, and purification of the residue by silica gel column chromatography (petroleum ether/ethyl acetate 9/1~5/1) afforded the pure product. Enantiomeric purity of the products formed was verified by HPLC analysis. HPLC conditions: column, CHIRAL-CEL (OD); mobile phase, 2~10% *i*-PrOH in *n*-hexane; flowrate, 1mL/min; UV detection at 225 nm.

Benzyl 3-phenylpropanoate (3a) (CAS no: 22767-96-0)




115 mg, 96% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.37 – 7.23 (m, 7H), 7.21 – 7.17 (m, 3H), 5.10 (s, 2H), 2.97 (t, $J = 7.8$ Hz, 2H), 2.68 (t, $J = 7.8$ Hz, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.7, 140.4, 135.9, 128.6, 128.5, 128.4, 128.3, 128.2, 126.2, 66.2, 35.9, 30.9. ESI-MS: m/z 241.0 ($[\text{M}+\text{H}]^+$).

Prop-2-yn-1-yl 3-phenylpropanoate (3b) (CAS no: 23522-64-7)




89 mg, 92% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.30 – 7.26 (m, 2H), 7.21 – 7.18 (m, 3H), 4.67 (d, $J = 2.5$ Hz, 2H), 2.96 (t, $J = 7.8$ Hz, 2H), 2.69 – 2.65 (m, 2H), 2.46 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 171.9, 140.1, 128.5, 128.2, 126.3, 77.6, 74.8, 51.9, 35.5, 30.7. ESI-MS: m/z 189.1 ($[\text{M}+\text{H}]^+$).

Cinnamyl 3-phenylpropanoate (3c) (CAS no: 28048-98-8)




120 mg, 90% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.36 (m, 2H), 7.33 – 7.24 (m, 5H), 7.23 – 7.17 (m, 3H), 6.61 (d, $J = 15.9$ Hz, 1H), 6.24 (dt, $J = 15.9, 6.4$ Hz, 1H), 4.72 (dd, $J = 6.5, 1.2$ Hz, 2H), 2.97 (t, $J = 7.8$ Hz, 2H), 2.67 (dd, $J = 9.3, 6.4$ Hz, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.6, 140.4, 136.1, 134.1, 128.6, 128.5, 128.3, 128.0, 126.6, 126.2, 123.1, 65.0, 35.9, 30.9. ESI-MS: m/z 267.1 ($[\text{M}+\text{H}]^+$).

(9H-fluoren-9-yl)Methyl 3-phenylpropanoate (3d)




154 mg, 94% yield. IR (KBr, film), ν_{max} (cm^{-1}): 3063, 3027, 2948, 2359, 1736, 1450, 1291, 1250, 1159, 758, 740, 699; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.74 (d, $J = 7.6$ Hz, 2H), 7.52 (dd, $J = 7.5, 0.7$ Hz, 2H), 7.38 (t, $J = 7.3$ Hz, 2H), 7.30 – 7.26 (m, 4H), 7.21 – 7.18 (m, 3H), 4.38 (d, $J = 7.1$ Hz, 2H), 4.16 (t, $J = 7.1$ Hz, 1H), 2.95 (t, $J = 7.8$ Hz, 2H), 2.72 – 2.68 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.8, 143.7, 141.3, 140.4, 128.5, 128.2, 127.7, 127.1, 126.3, 125.0, 112.0, 66.3, 46.8, 35.9, 30.8. HRMS(ESI): m/z 329.1549 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{21}\text{O}_2^+$ calcd. 329.1542).

Isopropyl 3-phenylpropanoate (3e) (CAS no: 22767-95-9)




90 mg, 94% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.30 – 7.25 (m, 2H), 7.21 – 7.17 (m, 3H), 5.00 (hept, $J = 6.3$ Hz, 1H), 2.94 (t, $J = 8.0$ Hz, 2H), 2.59 (t, $J = 8.0$ Hz, 2H), 1.20 (d, $J = 6.3$ Hz, 6H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.4, 140.6, 128.4, 128.3, 126.1, 67.6, 36.2, 31.0, 21.8. ESI-MS: m/z 193.3 ($[\text{M}+\text{H}]^+$).

(1*R*, 2*S*, 5*R*)-2-Isopropyl-5-methylcyclohexyl 3-phenylpropanoate (**3f**) (CAS no: 101023-15-8)




137 mg, 95% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.29 – 7.25 (m, 2H), 7.21 – 7.17 (m, 3H), 4.67 (td, $J = 10.9, 4.4$ Hz, 1H), 2.97 – 2.93 (m, 2H), 2.61 (dd, $J = 8.6, 7.0$ Hz, 2H), 1.96 – 1.90 (m, 1H), 1.76 – 1.70 (m, 1H), 1.69 – 1.62 (m, 2H), 1.53 – 1.40 (m, 1H), 1.37 – 1.29 (m, 1H), 1.08 – 0.98 (m, 1H), 0.96 – 0.91 (m, 1H), 0.90 – 0.88 (m, 3H), 0.86 – 0.84 (m, 4H), 0.70 (d, $J = 7.0$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.5, 140.5, 128.4, 128.3, 126.2, 74.1, 46.9, 40.9, 36.2, 34.2, 31.3, 31.1, 26.1, 23.4, 22.0, 20.7, 16.2. ESI-MS: m/z 289.3 ($[\text{M}+\text{H}]^+$).

Phenyl 3-phenylpropanoate (**3g**) (CAS no: 726-26-1)




103 mg, 91% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.37 – 7.30 (m, 4H), 7.27 – 7.18 (m, 4H), 7.01 – 6.98 (m, 2H), 3.07 (t, $J = 7.7$ Hz, 2H), 2.90 – 2.86 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 171.4, 150.6, 140.1, 129.4, 128.6, 128.4, 126.4, 125.8, 121.5, 35.9, 30.9. ESI-MS: m/z 227.1 ($[\text{M}+\text{H}]^+$).

Naphthalen-1-yl 3-phenylpropanoate (**3h**)




121 mg, 88% yield. IR (KBr, film), ν_{max} (cm^{-1}): 3061, 3028, 2927, 1759, 1598, 1496, 1454, 1390, 1258, 1221, 1125, 794, 771, 698; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.84 – 7.82 (m, 1H), 7.71 (d, $J = 8.3$ Hz, 1H), 7.57 (dt, $J = 8.5, 4.3$ Hz, 1H), 7.49 – 7.39 (m, 3H), 7.38 – 7.25 (m, 5H), 7.16 (dd, $J = 7.5, 1.0$ Hz, 1H), 3.19 – 3.14 (m, 2H), 3.09 – 3.04 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 171.4, 146.5, 140.1, 134.6, 128.7, 128.5, 127.9, 126.7, 126.5, 126.4, 126.3, 126.0, 125.3, 121.1, 118.0, 35.9, 31.0. HRMS(ESI): m/z 277.1240 ($[\text{M}+\text{H}]^+$, $\text{C}_{19}\text{H}_{17}\text{O}_2^+$ calcd. 277.1229).

Benzyl cinnamate (**3i**) (CAS no: 103-41-3)




107 mg, 90% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.73 (d, $J = 16.0$ Hz, 1H), 7.53 – 7.49 (m, 2H), 7.43 – 7.31 (m, 8H), 6.48 (d, $J = 16.0$ Hz, 1H), 5.25 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.8, 145.1, 136.0, 134.3, 130.3, 128.8, 128.6, 128.2, 128.2, 128.1, 117.8, 66.3. ESI-MS: m/z 239.3($[\text{M}+\text{H}]^+$).

Benzyl cyclohexanecarboxylate (3j) (CAS no: 22733-94-4)




98 mg, 90% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.28 (m, 5H), 5.10 (s, 2H), 2.39 – 2.31 (m, 1H), 1.95 – 1.90 (m, 2H), 1.78 – 1.71 (m, 2H), 1.65 – 1.60 (m, 1H), 1.51 – 1.41 (m, 2H), 1.32 – 1.16 (m, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 175.9, 136.3, 128.5, 128.0, 127.9, 65.8, 43.2, 28.9, 25.7, 25.4. ESI-MS: m/z 219.2($[\text{M}+\text{H}]^+$).

Benzyl isonicotinate (3k) (CAS no: 21182-01-4)




99 mg, 96% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.76 (dd, $J = 4.4, 1.6$ Hz, 2H), 7.86 (dd, $J = 4.4, 1.6$ Hz, 2H), 7.46 – 7.32 (m, 5H), 5.38 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.9, 150.5, 137.2, 135.2, 128.6, 128.5, 128.4, 128.3, 127.4, 126.9, 122.9, 67.4. ESI-MS: m/z 214.0($[\text{M}+\text{H}]^+$).

Benzyl benzoate (3l) (CAS no: 120-51-4)




95 mg, 90% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.09 – 8.07 (m, 2H), 7.57 – 7.52 (m, 1H), 7.46 – 7.31 (m, 7H), 5.36 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.4, 136.0, 133.0, 130.1, 129.7, 128.6, 128.3, 128.2, 128.1, 66.6. ESI-MS: m/z 213.0($[\text{M}+\text{H}]^+$).

Benzyl 4-methylbenzoate (3m) (CAS no: 5467-99-2)




96 mg, 85% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.98 – 7.95 (m, 2H), 7.45 – 7.42 (m, 2H), 7.39 – 7.30 (m, 3H), 7.23 – 7.21 (m, 2H), 5.34 (s, 2H), 2.39 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.5, 143.7, 136.1, 129.7, 129.0, 128.5, 128.1, 128.0, 127.3, 66.4, 21.6. ESI-MS: m/z 227.1($[\text{M}+\text{H}]^+$).

Benzyl 2-nitrobenzoate (3n) (CAS no: 7579-38-6)




123 mg, 96% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.91 – 7.88 (m, 1H), 7.75 – 7.73 (m, 1H), 7.67 – 7.58 (m, 2H), 7.42 – 7.32 (m, 5H), 5.35 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.2, 154.8, 148.1, 134.7, 132.9, 131.7, 129.8, 128.7, 128.6, 128.5, 127.5, 123.9, 89.7, 68.3. ESI-MS: m/z 258.2($[\text{M}+\text{H}]^+$).

Dodecyl stearate (3o) (CAS no: 5303-25-3)




193 mg, 90% yield. $^1\text{H NMR}$ (400MHz, CDCl_3) δ 4.06 (t, $J = 6.7\text{Hz}$, 2H), 2.30 (t, $J = 7.5\text{Hz}$, 2H), 1.62 (t, $J = 7.4\text{Hz}$, 4H), 1.26 (br s, 45H), 0.89 (t, $J = 6.8\text{Hz}$, 6H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.03, 64.39, 34.41, 31.92, 29.70, 29.66, 29.63, 29.61, 29.57, 29.53, 29.48, 29.36, 29.35, 29.27, 29.25, 29.16, 28.65, 25.93, 25.03, 22.68, 14.11. ESI-MS: m/z 453.4($[\text{M}+\text{H}]^+$).

Octadecyl stearate (3p) (CAS no: 2778-96-3)




236 mg, 88% yield. $^1\text{H NMR}$ (400MHz, CDCl_3) δ 4.05 (t, $J = 5.7\text{Hz}$, 2H), 2.29 (t, $J = 7.5\text{Hz}$, 2H), 1.63 (t, $J = 6.8\text{Hz}$, 4H), 1.26 (br s, 58H), 0.88 (t, $J = 6.9\text{Hz}$, 6H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.04, 64.40, 34.42, 31.92, 29.70, 29.65, 29.60, 29.58, 29.53, 29.48, 29.36, 29.27, 29.26, 29.16, 28.65, 25.94, 25.04, 22.69, 14.11. ESI-MS: m/z 537.8($[\text{M}+\text{H}]^+$).

Cholest-5-en-3-ol (3β)-, 3-benzenepropanoate (3q) (CAS no: 14914-99-9)




197 mg, 76% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.23 – 7.18 (m, 2H), 7.13 – 7.10 (m, 3H), 5.29 (d, $J = 4.0\text{ Hz}$, 1H), 4.57 – 4.50 (m, 1H), 2.87 (t, $J = 7.8\text{ Hz}$, 2H), 2.52 (t, $J = 7.8\text{ Hz}$, 2H), 2.21 (d, $J = 7.8\text{ Hz}$, 2H), 1.96 – 1.86 (m, 2H), 1.80 – 1.71 (m, 3H), 1.54 – 1.36 (m, 8H), 1.34 – 1.13 (m, 5H), 1.11 – 0.95 (m, 8H), 0.94 (s, 3H), 0.84 (d, $J = 6.5\text{ Hz}$, 3H), 0.80 (d, $J = 1.7\text{ Hz}$, 3H), 0.79 (d, $J = 1.7\text{ Hz}$, 3H), 0.60 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.3, 140.6, 139.7, 128.4, 128.3, 126.2, 122.6, 74.0, 56.7, 56.2, 50.1, 42.3, 39.8, 39.5, 38.1, 37.0, 36.6, 36.3, 36.2, 35.8, 31.9, 31.8, 31.1, 28.2, 28.0, 27.8, 24.3, 23.8, 22.8, 22.5, 21.0, 19.3, 18.7, 11.9. ESI-MS: m/z 519.4($[\text{M}+\text{H}]^+$).

N-Butyl-3-phenylpropanamide (5a) (CAS no: 10264-11-6)




97 mg, 95% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.30 – 7.26 (m, 2H), 7.23 – 7.17 (m, 3H), 5.39 (s, 1H), 3.20 (td, $J = 7.1, 5.8$ Hz, 2H), 2.96 (t, $J = 8.0$ Hz, 2H), 2.45 (t, $J = 8.0$ Hz, 2H), 1.43 – 1.36 (m, 2H), 1.30 – 1.21 (m, 2H), 0.88 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.0, 140.9, 128.5, 128.3, 126.2, 39.2, 38.6, 31.8, 31.6, 19.9, 13.7. ESI-MS: m/z 228.1($[\text{M}+\text{Na}]^+$).

3-Phenyl-1-(piperidin-1-yl)propan-1-one (5b) (CAS no: 21924-11-8)




95 mg, 88% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.30 – 7.25 (m, 2H), 7.22 – 7.17 (m, 3H), 3.55 (t, $J = 5.6$ Hz, 2H), 3.32 (t, $J = 5.6$ Hz, 2H), 2.96 (t, $J = 8.0$ Hz, 2H), 2.61 (dd, $J = 9.0, 7.0$ Hz, 2H), 1.63 – 1.57 (m, 2H), 1.54 – 1.42 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.4, 141.4, 128.4, 128.3, 125.9, 46.5, 42.6, 35.0, 31.5, 26.3, 25.4, 24.4. ESI-MS: m/z 240.2($[\text{M}+\text{Na}]^+$).

N,N-Diallyl-3-phenylpropanamide (5c) (CAS no: 101104-56-7)




94 mg, 82% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.17 (m, 2H), 7.14 – 7.08 (m, 3H), 5.72-5.7 (m, 2H), 5.10 – 4.98 (m, 4H), 3.91 (d, $J = 6.0$ Hz, 2H), 3.72 (dt, $J = 4.6, 1.7$ Hz, 2H), 2.91 (t, $J = 8.0$ Hz, 2H), 2.56 – 2.52 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 141.3, 133.3, 132.8, 128.4, 126.0, 117.1, 116.5, 49.0, 47.9, 34.8, 31.4. ESI-MS: m/z 252.0($[\text{M}+\text{Na}]^+$).

N,3-Diphenylpropanamide (5d) (CAS no: 3271-81-6)




101 mg, 90% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.55 (s, 1H), 7.34 (d, $J = 7.8$ Hz, 2H), 7.19 – 7.14 (m, 4H), 7.11 – 7.07 (m, 3H), 6.97 (t, $J = 7.4$ Hz, 1H), 2.91 (t, $J = 7.7$ Hz, 2H), 2.52 (t, $J = 7.7$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.7, 140.6, 137.8, 128.8, 128.5, 128.3, 126.3, 124.2, 120.1, 39.2, 31.5. ESI-MS: m/z 248.1($[\text{M}+\text{Na}]^+$).

N-(4-methoxyphenyl)-3-phenylpropanamide (5e) (CAS no: 97754-31-9)



117 mg, 92% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.29 (s, 1H), 7.23 – 7.17 (m, 4H), 7.13 – 7.10 (m, 3H), 6.71 (dd, $J = 12.0, 2.8$ Hz, 2H), 3.69 (s, 3H), 2.93 (t, $J = 7.7$ Hz, 2H), 2.52 (t, $J = 7.7$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.4, 156.4, 140.7, 130.9, 128.5, 128.3, 126.3, 122.0, 114.0, 55.4, 39.1, 31.6. ESI-MS: m/z 278.0($[\text{M}+\text{Na}]^+$).


3-Phenyl-N-(o-tolyl)propanamide (5f) (CAS no: 71231-24-8)



104 mg, 87% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.59 (d, $J = 7.9$ Hz, 1H),

7.23 – 7.11 (m, 5H), 7.10 – 7.03 (m, 2H), 6.96 (t, $J = 7.3$ Hz, 1H), 6.88 (s, 1H), 2.96 (t, $J = 7.5$ Hz, 2H), 2.60 (t, $J = 7.5$ Hz, 2H), 1.96 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 170.4, 140.5, 135.5, 130.4, 129.4, 128.6, 128.4, 126.6, 126.4, 125.2, 123.4, 39.1, 31.7, 17.5. ESI-MS: m/z 262.0($[\text{M}+\text{Na}]^+$).


N-Butylbenzamide (**5g**) (CAS no: 2782-40-3)



84 mg, 95% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.70 – 7.67 (m, 2H), 7.40 – 7.35

(m, 1H), 7.32 – 7.28 (m, 2H), 6.44 (s, 1H), 3.34 (dd, $J = 13.5, 6.6$ Hz, 2H), 1.53 – 1.46 (m, 2H), 1.35 – 1.26 (m, 2H), 0.85 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 167.6, 134.8, 131.1, 128.4, 126.8, 39.7, 31.6, 20.1, 13.7. ESI-MS: m/z 200.2($[\text{M}+\text{Na}]^+$).


N-Butyl-4-methylbenzamide (**5h**) (CAS no: 5456-97-3)



88 mg, 92% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.60 – 7.58 (m, 2H), 7.11 (d, J

$= 7.9$ Hz, 2H), 6.32 (s, 1H), 3.34 (td, $J = 7.2, 5.8$ Hz, 2H), 2.29 (s, 3H), 1.53 – 1.46 (m, 2H), 1.33 – 1.28 (m, 2H), 0.86 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 167.5, 141.5, 131.9, 129.0, 126.8, 39.7, 31.7, 21.3, 20.1, 13.7. ESI-MS: m/z 214.1($[\text{M}+\text{Na}]^+$).


N-Butyl-4-ethoxybenzamide (**5i**) (CAS no: 6283-99-4)



93 mg, 84% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66 – 7.62 (m, 2H), 6.84

– 6.80 (m, 2H), 5.99 (s, 1H), 4.00 (q, $J = 7.0$ Hz, 2H), 3.36 (td, $J = 7.1, 5.8$ Hz, 2H), 1.55 – 1.48 (m, 2H), 1.38 – 1.29 (m, 5H), 0.91 – 0.86 (m, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 167.1, 161.5, 128.6, 127.0, 114.2, 63.6, 39.7, 31.8, 20.2, 14.7, 13.8. ESI-MS: m/z 244.2($[\text{M}+\text{Na}]^+$).


N-Butyl-4-chlorobenzamide (**5j**) (CAS no: 1455-99-8)



101 mg, 96% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.62 (d, $J = 8.5$ Hz, 2H),


7.28 (d, $J = 8.5$ Hz, 2H), 6.43 (s, 1H), 3.33 (dd, $J = 13.2, 6.9$ Hz, 2H), 1.54 – 1.46 (m, 2H), 1.35 – 1.26 (m, 2H), 0.86 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.5, 137.4, 133.2, 128.6, 128.3, 39.9, 31.6, 20.1, 13.7. ESI-MS: m/z 244.2($[\text{M}+\text{Na}]^+$). ESI-MS: m/z 234.1($[\text{M}+\text{Na}]^+$).

N-Butyl-4-nitrobenzamide (**5k**) (CAS no: 51207-98-8)




107 mg, 96% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.19 – 8.16 (m, 2H), 7.87 – 7.84 (m, 2H), 6.46 (s, 1H), 3.39 (td, *J* = 7.2, 5.8 Hz, 2H), 1.58 – 1.51 (m, 2H), 1.38 – 1.29 (m, 2H), 0.88 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 149.4, 140.4, 128.1, 123.7, 40.1, 31.5, 20.1, 13.7. ESI-MS: *m/z* 245.3([M+Na]⁺).

Cbz-Phe-Leu-OMe (**5l**) (CAS no: 3580-45-1)




203 mg, 95% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 5H), 7.27 – 7.22 (m, 3H), 7.21 – 7.17 (m, 2H), 6.30 (d, *J* = 7.6 Hz, 1H), 5.39 (d, *J* = 7.6 Hz, 1H), 5.08 (s, 2H), 4.58 – 4.53 (m, 1H), 4.50 – 4.46 (m, 1H), 3.69 (s, 3H), 3.13 – 3.02 (m, 2H), 1.60 – 1.41 (m, 3H), 0.88 (t, *J* = 6.2 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 172.8, 170.6, 155.9, 136.2, 136.0, 129.3, 128.6, 128.5, 128.2, 128.0, 127.0, 67.0, 55.9, 52.2, 50.7, 41.4, 38.3, 24.6, 22.6, 21.8; ESI-MS: *m/z* 449.2([M+Na]⁺). HPLC retention time = 12.0 min (mobile phase, 7% *i*-PrOH in *n*-hexane).

Cbz-Ala-Ala-OMe (**5m**), (CAS no: 2483-51-4)




145 mg, 94% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 5H), 6.79 (d, *J* = 6.3 Hz, 1H), 5.56 (d, *J* = 7.4 Hz, 1H), 5.14 – 5.07 (m, 2H), 4.56 (p, *J* = 7.2 Hz, 1H), 4.33 – 4.29 (m, 1H), 3.74 (s, 3H), 1.38 (d, *J* = 7.0 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 173.1, 171.9, 155.9, 136.1, 128.5, 128.1, 128.0, 66.9, 52.4, 50.3, 48.0, 18.7, 18.1. ESI-MS: *m/z* 331.1([M+Na]⁺). HPLC retention time = 15.8 min (mobile phase, 10% *i*-PrOH in *n*-hexane).

Boc-Ile-Val-OMe (**5n**) (CAS no: 33911-17-0)




143 mg, 83% yield. ¹H NMR (400 MHz, CDCl₃) δ 6.45 (d, *J* = 8.3 Hz, 1H), 5.11 (d, *J* = 8.6 Hz, 1H), 4.55 (dd, *J* = 8.7, 4.9 Hz, 1H), 3.96 (dd, *J* = 16.6, 8.7 Hz, 1H), 3.74 (s, 3H), 2.24 – 2.12 (m, 1H), 1.88 – 1.86 (m, 1H), 1.57 – 1.51 (m, 1H), 1.44 (s, 9H), 1.21 – 1.10 (m, 1H), 0.95 – 0.90 (m, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 171.6, 155.7, 79.8, 59.3, 57.0, 52.1, 36.9, 31.2, 28.2, 24.7, 18.9, 17.7, 15.4, 11.3. ESI-MS: *m/z* 367.4([M+Na]⁺). HPLC retention time = 10.4 min (mobile phase, 2% *i*-PrOH in *n*-hexane).

Boc-Val-Val-OMe (**5o**) (CAS no: 33857-88-4)




159 mg, 96% yield. ^1H NMR (400 MHz, CDCl_3) δ 6.47 (d, $J = 8.1$ Hz, 1H), 5.12 (d, $J = 8.6$ Hz, 1H), 4.55 (dd, $J = 8.7, 4.9$ Hz, 1H), 3.93 (dd, $J = 10.6, 4.6$ Hz, 1H), 3.74 (s, 3H), 2.22 – 2.10 (m, 2H), 1.45 (s, 9H), 0.98 – 0.90 (m, 12H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 171.9, 171.6, 162.9, 155.8, 79.8, 60.1, 57.0, 52.1, 31.1, 30.6, 28.2, 19.2, 18.9, 17.9, 17.7. ESI-MS: m/z 353.2($[\text{M}+\text{Na}]^+$). HPLC retention time = 6.6 min (mobile phase, 2% *i*-PrOH in *n*-hexane).

Boc-Phe-Gly-OEt (**5p**) (CAS no: 30189-51-6)




159 mg, 91% yield. ^1H -NMR (400 MHz, CDCl_3) δ (ppm) 1.27 (t, $J = 7.1$ Hz, 3H), 1.39 (s, 9H), 3.05 (m, 1H), 3.13 (dd, $J = 6.5, 13.9$ Hz, 1H), 3.92 (dd, $J = 4.9, 18.3$ Hz, 1H), 4.02 (dd, $J = 5.4, 18.2$ Hz, 1H), 4.19 (q, $J = 7.1$ Hz, 2H), 4.43 (d, $J = 6.2$ Hz, 1H), 5.11 (br d, $J = 7.2$ Hz, 1H), 6.57 (t, $J = 5.0$ Hz, 1H), 7.20-7.31(m,5H) ; ^{13}C -NMR (100 MHz, CDCl_3) δ (ppm) 171.5, 169.4, 155.4, 136.6, 129.2, 128.6, 126.9, 80.2, 61.5, 55.5, 41.3, 38.3, 28.2, 14.1, 1.0; ESI-MS: m/z 373.2 ($[\text{M}+\text{Na}]^+$); HPLC retention time = 13.6 min (mobile phase, 7% *i*-PrOH in *n*-hexane);

Boc-Phe-Ala-OMe (**5q**) (CAS no: 15136-29-5)





159 mg, 91% yield. ^1H -NMR (400 MHz, CDCl_3) δ (ppm) 1.35 (d, $J = 7.2$ Hz, 3H), 1.40 (s, 9H), 3.07 (d, $J = 6.5$ Hz, 2H), 3.71 (s, 3H), 4.39 (d, $J = 6.2$ Hz, 1H), 4.52 (p, $J = 7.1$ Hz, 1H), 5.08 (br d, $J = 5.9$ Hz, 1H), 6.55 (br d, $J = 5.6$ Hz, 1 H), 7.20-7.31 (m,5H); ^{13}C -NMR (100 MHz, CDCl_3) δ (ppm) 172.8, 170.8, 155.3, 136.5, 129.3, 128.6, 126.9, 80.1, 55.5, 52.4, 48.0, 38.3, 28.2, 18.3; ESI-MS: m/z : 373.2($[\text{M}+\text{Na}]^+$); HPLC retention time = 11.7 min (mobile phase, 7% *i*-PrOH in *n*-hexane);

Boc-Val-Leu-OMe (**5r**) (CAS no: 15215-73-3)





151 mg, 88% yield. ^1H -NMR (400 MHz, CDCl_3) δ (ppm) 0.92-0.98 (m, 12H), 1.44 (s, H), 1.54-1.58 (m, 1H), 1.60-1.69 (m, 1H), 2.08-2.13 (m, 1H), 3.73 (s, 3H), 3.92 (dd, $J = 6.8, 8.6$ Hz, 1H), 4.59-4.65 (m, 1H), 5.13 (br d, $J = 8.8, 1$ H), 6.41 (br d, $J = 7.8$ Hz, 1H); ^{13}C -NMR (100 MHz, CDCl_3) δ (ppm) 173.1, 171.5, 155.8, 79.8, 59.8, 52.2, 50.6, 41.3, 30.8, 28.2, 24.7, 22.7, 21.8, 19.1, 17.8; ESI-MS: m/z 367.3($[\text{M}+\text{Na}]^+$); HPLC retention time = 10.3 min (mobile phase, 2% *i*-PrOH in *n*-hexane).



3a





3b



3c




3d


CDCl₃CDCl₃

3e



CDCl₃



CDCl₃




3f




3g



CDCl₃



CDCl₃




3h




3i



CDCl₃





CDCl₃





3j






3m




3n

CDCl₃




CDCl₃




30

CDC13




CDC13




3p



CDC13



CDC13




3q




5a

CDCl₃




CDCl₃




5b

CDCl₃




CDCl₃




5c

CDCl₃




CDCl₃




5d

CDCl₃




CDCl₃




5e

CDCl₃




CDCl₃




5f

CDCl₃




CDCl₃




5g

CDCl₃




CDCl₃




5h

CDCl₃




CDCl₃




5i

CDCl₃




CDCl₃




5j

CDCl₃




CDCl₃







5k

CDCl₃




CDCl₃






PEAK#	RT(min)	AREA	AREA%
1	11.97	10263	49.7
2	18.50	10397	50.3





PEAK#	RT(min)	AREA	AREA%
1	12.03	9801	99.5
2	19.03	54	0.5

5m


z-Ala-Ala-OMe
CDCl₃



z-Ala-Ala-OMe
CDCl₃




PEAK#	RT (min)	AREA	AREA%
1	15.63	4464	70.8
2	21.30	1840	29.2





PEAK#	RT (min)	AREA	AREA%
1	15.77	3796	99.5
2	24.63	17	0.5

5n


Boc-Ile-Val-OMe
CDCl₃



Boc-Ile-Val-OMe
CDCl₃




PEAK#	RT (min)	AREA	AREA%
1	6.03	5306	57.7
2	8.97	3890	42.3





PEAK#	RT (min)	AREA	AREA%
1	6.10	4828	99.8
2	9.23	8	0.2

50


Boc-Val-Val-OMe
CDCl₃



Boc-Val-Val-OMe
CDCl₃







PEAK#	RT(min)	AREA	AREA%
1	6.50	4372	56.4
2	9.30	3384	43.6



PEAK#	RT(min)	AREA	AREA%
1	6.57	4340	99.9
2	9.77	4	0.1





5p



PEAK#	RT (min)	AREA	AREA%
1	10.43	4346	46.9
2	14.43	4915	53.1

PEAK#	RT (min)	AREA	AREA%
1	10.50	54	0.4
2	13.57	12034	99.6




5q




PEAK#	RT(min)	AREA	AREA%
1	9.17	11465	50.9
2	11.63	11075	49.1

PEAK#	RT(min)	AREA	AREA%
1	9.23	100	1.1
2	11.70	9280	98.9

5r



PEAK#	RT (min)	AREA	AREA%
1	6.03	3868	54.3
2	9.23	3252	45.7



PEAK#	RT (min)	AREA	AREA%
1	6.03	4199	100.0